Llwytho...
4CPS-128 Effectiveness of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
BACKGROUND: Abiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis. PURPOSE: To compare the effectiveness of AA and enzalutamide in patients with mCRPC. MATERIAL A...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Eur J Hosp Pharm |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BMJ Group
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535815/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.219 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|